APR 03, 2019 8:58 PM PDT

A Novel Therapeutic Target for a Severe Bacterial Infection

Electron scanning microscope image of Pseudomonas by Janice Haney Carr

Pseudomonas aeruginosa (Pa) is an opportunistic human pathogen that can cause severe illness and even death in people that are hospitalized or have weakened immune systems. Further complicating Pa infections is the pathogen’s high rate of antibiotic resistance. Indeed, the CDC has given multidrug-resistant Pseudomonas a threat level of serious. Researchers at Stanford University found that a bacteriophage harbored by Pa contributes to its pathogenesis. They demonstrate in Science magazine that targeting this phage is a successful non-antibiotic therapy that leads to Pa clearance.

As an opportunistic pathogen, Pseudomonas aeruginosa exploits breaks in the host defenses to infection. Though Pseudomonas species normally inhabit soil, water, and vegetation, Pa can infect almost any compromised tissue. Pa is associated with chronic wounds and other infections such as urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections. Patients who are immunosuppressed or have cystic fibrosis, severe burns, or cancer are particularly susceptible to infection. Only a few antibiotics are effective against Pa, and multidrug-resistant strains are currently on the rise in hospitals. Thus, Pa represents a deadly and ever-increasing threat to patients in critical care.


Researchers in the Bollyky lab in the Division of Infectious Diseases and Geographic Medicine, Department of Medicine, at Stanford University, previously showed that a filamentous Pf bacteriophage (Pf phage) promoted chronic Pa infection in the lung by reducing inflammation. To build on that work, they sought to determine how Pf phage contributed to Pa infection in chronic wounds. After sampling chronic wounds in over one hundred patients, they detected Pf phage in 68% of the Pa-infected chronic wounds. Pf-positive strains of Pa were also more frequent in older chronic wounds and in the wounds of younger patients.

Using a mouse model of Pa-infected chronic wounds, they learned that Pf phage entered human cells, produced RNA and triggered viral immunity. This inhibited bacterial clearance and allowed Pa to persist in the wound. Since Pf phage was preventing Pa from being cleared by the immune system, they next vaccinated animals against Pf phage before Pa infection in their chronic wound model. Amazingly, prior vaccination against Pf phage allowed the immune system to clear Pa infection! Administering monoclonal antibodies against Pf phage to fresh wounds also resulted in successful clearance of Pa. Hopefully, similar results will be seen in patients.

“We envision that individuals newly diagnosed with cystic fibrosis or diabetes could be immunized against Pf phage to prevent subsequent Pseudomonas infections. It might even be possible to administer antibodies to burn victims before Pseudomonas infections set in.” -Paul Bollyky

Pseudomonas aeruginosa is a serious, potentially fatal pathogen in susceptible populations. It is surprising to learn that Pf phage has a pathogenic role in Pa infection. Future work will examine if other bacteriophages also modulate non-bacterial cells and if targeting Pf phage leads to immune clearance of multidrug-resistant Pseudomonas. Pf phage is a novel target for treatment of Pa-infected chronic wounds. Successful development of a Pf phage vaccine could mean that Pseudomonas aeruginosa chronic infections are no longer life-threatening.

The Science magazine article referred to in this article can be found here.

 

Check out the video above to learn more about Pa infections.


 

About the Author
  • Aleishia is a freelance medical/science writer that specializes in research-oriented content. Contact her for work.
You May Also Like
MAR 23, 2020
Drug Discovery & Development
Is Fast-Tracking Vaccines for Coronavirus Really Such a Good Idea?
MAR 23, 2020
Is Fast-Tracking Vaccines for Coronavirus Really Such a Good Idea?
Donald Trump has called on researchers to “slash red tape like nobody has even done it before” to accelerate ...
APR 07, 2020
Microbiology
Second COVID-19 Vaccine Enters Human Trials
APR 07, 2020
Second COVID-19 Vaccine Enters Human Trials
Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19.
APR 13, 2020
Drug Discovery & Development
Are COVID-19 Antibody Tests a Back-to-Work Pass?
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 22, 2020
Drug Discovery & Development
Only 3% of COVID-19 Antibody Tests Approved by FDA
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 10, 2020
Drug Discovery & Development
Cancer Therapy Drug Reverses Kidney Damage
APR 10, 2020
Cancer Therapy Drug Reverses Kidney Damage
According to a study published in the journal Science Translational Medicine, a therapeutic previously used for cancer t ...
JUN 18, 2020
Neuroscience
How Climate Change Worsened Zika Virus Defects
JUN 18, 2020
How Climate Change Worsened Zika Virus Defects
Image: Pixabay   In 2015 a massive outbreak of the Zika virus started in Brazil and spread across 33 countries. The ...
Loading Comments...